June Off to a Poor ...
Health Care: Drugs
Amgen Inc (AMGN: NASDAQ)
$67.75 -1.77 | -2.55%
06/01/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 67.75 |
| 52 Week High | 72.00 |
| 52 Week Low | 47.66 |
| Avg. Daily Vol. (Mil) | 4.13 |
| Beta (3 year) | 0.62 |
| Share Related Items | |
| Mkt Cap (Mil) | 52,689.71 |
| Shares Out (Mil) | 777.71 |
| Float (Mil) | 781.68 |
| Dividend Information | |
| Yield % | 2.10 |
| Annual Dividend | 1.44 |
| Payout Ratio | 21.00 |
| Financial Strength | |
| Quick Ratio | 2.70 |
| Current Ratio | 3.20 |
| LT Debt/ Equity | 1.01 |
| Total Debt / Equity | 1.13 |
| Valuation Ratios | |
| Price Earnings | 15.70 |
| Price/Sales | 3.31 |
| Price/Book | 2.79 |
| Price/Cash Flow | 11.00 |
| Per Share Data | |
| Earnings | 4.31 |
| Sales | 20.48 |
| Book Value | 24.27 |
| Cash Flow | 6.16 |
| Business Summary | |
|---|---|
| Amgen Inc. is an independent biotechnology medicines company. It discovers, develops, manufactures and markets medicines for grievous illnesses. | |
| General Information | |
| One Amgen Center Drive
Thousand Oaks, CA 91320-1799 |
|
| www.Amgen.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 17500 | |
| CEO: Mr. Robert A. Bradway | |
| Short Interest | |
| Current Month (Mil) | 14.46 |
| Previous Month (Mil) | 14.26 |
| Short Interest Ratio (Days) | 3.50 |
| Management Effectiveness | |
| Return on Equity | 19.80 |
| Return on Assets | 7.60 |
| Return on Investments | 9.90 |
| Profitability | |
| Gross Margin | 88.80 |
| EBIT Margin | 30.90 |
| Profit Margin | 23.50 |
Portfolios with AMGN
- Portfolio NameUser Type
- UserLong Term Stock Picks by Co...
- Contributor5 Low Volatility Low PEG St...
- UserJimboPhi
- UserCorporate Communication cla...
- UserKAREL VON ZOETE
- UserMACHINE RECOMMENDATIONS
- UserMARIA DEL HUERTO
- ContributorHighest-Yielding Drug Stocks
- Contributor10 Health Care Stocks to Watch
- ContributorMost-Searched Stocks for th...
Latest AMGN Headlines from TheStreet
- Symmetry Projections
05.21.12 | 08:05 am - Amgen Inc (AMGN): Today's Featured Drugs Loser 05.18.12 | 05:05 pm
- 5 Cheap, Low-Risk Stocks to Buy 05.18.12 | 07:05 am
- Amgen Stock To Go Ex-dividend Monday (AMGN) 05.11.12 | 08:05 am
- Ex-Dividend Stocks: Target, ConEd 05.11.12 | 07:05 am
- Amgen Inc (AMGN): Today's Featured Drugs Winner 05.10.12 | 05:05 pm
- Amgen Inc (AMGN): Today's Featured Drugs Winner 05.02.12 | 04:05 pm
- Amgen Reaches New 52-Week High (AMGN) 04.25.12 | 01:04 pm
- Amgen Goes to Turkey, Loses Biotech Cred 04.25.12 | 09:04 am
- Amgen's CEO Discusses Q1 2012 Results - Earnings Call Transcript 04.24.12 | 10:04 pm
Press Releases for AMGN
- Amgen Announces Voting Results Of Annual Meeting Of Stockholders - PR Newswire 05.23.12 | 05:05 pm
- Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia - PR Newswire 05.16.12 | 06:05 pm
- Analysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - PR Newswire 05.16.12 | 06:05 pm
- Amgen To Present At The Baird Growth Stock Conference - PR Newswire 05.04.12 | 04:05 pm
- Amgen To Present At The Deutsche Bank 37th Annual Healthcare Conference - PR Newswire 05.03.12 | 06:05 pm
- Amgen Receives Complete Response Letter From FDA For XGEVA® SBLA For Prevention Of Bone Metastases - PR Newswire 04.26.12 | 10:04 pm
- Amgen To Acquire Mustafa Nevzat, A Leading Privately Held Turkish Pharmaceutical Company - PR Newswire 04.25.12 | 02:04 am
- A Tribute To George Rathmann, Amgen's Founding CEO (1927-2012) - PR Newswire 04.23.12 | 10:04 pm
- Amgen To Acquire Privately Held KAI Pharmaceuticals - PR Newswire 04.10.12 | 08:04 am
- UCB And Amgen Initiate Sclerostin Antibody Phase 3 Program In Patients With Postmenopausal Osteoporosis - PR Newswire 04.04.12 | 01:04 am
Partner Headlines for AMGN
- Health Care SPDR In Focus Ahead Of Obamacare Decision - Benzinga 05.22.12 | 12:05 pm
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
- Top Undervalued High Conviction Outperforming Picks From Eaton Vance's $47 Billion Q1 Filng - Seeking Alpha 04.20.12 | 10:04 pm
- Earnings Preview: Abbott Labs - Analyst Blog - Zacks 04.17.12 | 10:04 am
- The Zacks Analyst Blog Highlights: The Goldman Sachs Group, Lloyd's, Bank of America, JPMorgan Chase and Amgen - Press Releases - Zacks 04.12.12 | 09:04 am
- Market Roundup - Benzinga 04.10.12 | 01:04 pm
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Amgen, Abbott, Teva All Incredibly Undervalued Stocks - Seeking Alpha 04.06.12 | 07:04 am
